Hc Biosciences

Preclinical stage biotech company focused on the development of first-in-class tRNA-based therapeutics to treat diseases caused by nonsense mutations. The platform has the potential to deliver tRNA therapeutic drugs that can treat diseases in multiple categories as nonsense mutations are the cause of 10-15% of all genetically inherited disorders or cancers (examples include DMD, CF, spinal muscular atrophy, numerous metabolic disorders and cancers).